APO RESEARCH · REPORT
Anti-tumor Drug
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Product & engineering
Understand the product.
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Selected research
Industry Research
Anti-tumor Drug Industry Research Report 2026
Market perspective
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
Read the full market overview
Report Scope
This report quantifies the global Anti-tumor Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti-tumor Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-tumor Drug Market by Company
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Anti-tumor Drug Segment by Type
Cytotoxic Drugs
Non-cytotoxic Drugs
Anti-tumor Drug Segment by Application
Alkylating Agents
Anti-Metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline Antitumor Drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
Anti-tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti-tumor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cytotoxic Drugs
- Non-cytotoxic Drugs
Applications
- Alkylating Agents
- Anti-Metabolism Drugs
- Platinum Antineoplastic Agents
- Anthracycline Antitumor Drugs
- Microtubule Stabilizer
- Endocrine Therapy Drugs
- Immunotherapy Drugs
- Gene Therapy Drugs
- Targeted Antineoplastic Drugs
Companies covered
- Roche
- Novartis
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- Pfizer
- Takeda
- Eli Lilly
- AstraZeneca
- Astellas
- Merck & Co
- Sanofi
- Bayer
- Biogen Idec
- Eisai
- Teva
- Otsuka
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti-tumor Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cytotoxic Drugs
- 2.2.3 Non-cytotoxic Drugs
- 2.3 Anti-tumor Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Alkylating Agents
- 2.3.3 Anti-Metabolism Drugs
- 2.3.4 Platinum Antineoplastic Agents
- 2.3.5 Anthracycline Antitumor Drugs
- 2.3.6 Microtubule Stabilizer
- 2.3.7 Endocrine Therapy Drugs
- 2.3.8 Immunotherapy Drugs
- 2.3.9 Gene Therapy Drugs
- 2.3.10 Targeted Antineoplastic Drugs
- 2.4 Assumptions and Limitations
3 Anti-tumor Drug Breakdown Data by Type
- 3.1 Global Anti-tumor Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Anti-tumor Drug Forecasted Market Size by Type (2027-2032)
4 Anti-tumor Drug Breakdown Data by Application
- 4.1 Global Anti-tumor Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Anti-tumor Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti-tumor Drug Market Perspective (2021-2032)
- 5.2 Global Anti-tumor Drug Growth Trends by Region
- 5.2.1 Global Anti-tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti-tumor Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Anti-tumor Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Anti-tumor Drug Market Dynamics
- 5.3.1 Anti-tumor Drug Industry Trends
- 5.3.2 Anti-tumor Drug Market Drivers
- 5.3.3 Anti-tumor Drug Market Challenges
- 5.3.4 Anti-tumor Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti-tumor Drug Players by Revenue
- 6.1.1 Global Top Anti-tumor Drug Players by Revenue (2021-2026)
- 6.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti-tumor Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti-tumor Drug Head Office and Area Served
- 6.4 Global Anti-tumor Drug Players, Product Type & Application
- 6.5 Global Anti-tumor Drug Manufacturers Established Date
- 6.6 Global Anti-tumor Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti-tumor Drug Market Size (2021-2032)
- 7.2 North America Anti-tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti-tumor Drug Market Size by Country (2021-2026)
- 7.4 North America Anti-tumor Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti-tumor Drug Market Size (2021-2032)
- 8.2 Europe Anti-tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti-tumor Drug Market Size by Country (2021-2026)
- 8.4 Europe Anti-tumor Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-tumor Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Anti-tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti-tumor Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti-tumor Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti-tumor Drug Market Size (2021-2032)
- 10.2 South America Anti-tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti-tumor Drug Market Size by Country (2021-2026)
- 10.4 South America Anti-tumor Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-tumor Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Anti-tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti-tumor Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti-tumor Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Anti-tumor Drug Business (2021-2026)
- 12.1.4 Roche Anti-tumor Drug Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Anti-tumor Drug Business (2021-2026)
- 12.2.4 Novartis Anti-tumor Drug Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Celgene
- 12.3.1 Celgene Company Information
- 12.3.2 Celgene Business Overview
- 12.3.3 Celgene Revenue in Anti-tumor Drug Business (2021-2026)
- 12.3.4 Celgene Anti-tumor Drug Product Portfolio
- 12.3.5 Celgene Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Anti-tumor Drug Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Amgen
- 12.5.1 Amgen Company Information
- 12.5.2 Amgen Business Overview
- 12.5.3 Amgen Revenue in Anti-tumor Drug Business (2021-2026)
- 12.5.4 Amgen Anti-tumor Drug Product Portfolio
- 12.5.5 Amgen Recent Developments
- 12.6 Johnson & Johnson
- 12.6.1 Johnson & Johnson Company Information
- 12.6.2 Johnson & Johnson Business Overview
- 12.6.3 Johnson & Johnson Revenue in Anti-tumor Drug Business (2021-2026)
- 12.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
- 12.6.5 Johnson & Johnson Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Anti-tumor Drug Business (2021-2026)
- 12.7.4 Pfizer Anti-tumor Drug Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Takeda
- 12.8.1 Takeda Company Information
- 12.8.2 Takeda Business Overview
- 12.8.3 Takeda Revenue in Anti-tumor Drug Business (2021-2026)
- 12.8.4 Takeda Anti-tumor Drug Product Portfolio
- 12.8.5 Takeda Recent Developments
- 12.9 Eli Lilly
- 12.9.1 Eli Lilly Company Information
- 12.9.2 Eli Lilly Business Overview
- 12.9.3 Eli Lilly Revenue in Anti-tumor Drug Business (2021-2026)
- 12.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
- 12.9.5 Eli Lilly Recent Developments
- 12.10 AstraZeneca
- 12.10.1 AstraZeneca Company Information
- 12.10.2 AstraZeneca Business Overview
- 12.10.3 AstraZeneca Revenue in Anti-tumor Drug Business (2021-2026)
- 12.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
- 12.10.5 AstraZeneca Recent Developments
- 12.11 Astellas
- 12.11.1 Astellas Company Information
- 12.11.2 Astellas Business Overview
- 12.11.3 Astellas Revenue in Anti-tumor Drug Business (2021-2026)
- 12.11.4 Astellas Anti-tumor Drug Product Portfolio
- 12.11.5 Astellas Recent Developments
- 12.12 Merck & Co
- 12.12.1 Merck & Co Company Information
- 12.12.2 Merck & Co Business Overview
- 12.12.3 Merck & Co Revenue in Anti-tumor Drug Business (2021-2026)
- 12.12.4 Merck & Co Anti-tumor Drug Product Portfolio
- 12.12.5 Merck & Co Recent Developments
- 12.13 Sanofi
- 12.13.1 Sanofi Company Information
- 12.13.2 Sanofi Business Overview
- 12.13.3 Sanofi Revenue in Anti-tumor Drug Business (2021-2026)
- 12.13.4 Sanofi Anti-tumor Drug Product Portfolio
- 12.13.5 Sanofi Recent Developments
- 12.14 Bayer
- 12.14.1 Bayer Company Information
- 12.14.2 Bayer Business Overview
- 12.14.3 Bayer Revenue in Anti-tumor Drug Business (2021-2026)
- 12.14.4 Bayer Anti-tumor Drug Product Portfolio
- 12.14.5 Bayer Recent Developments
- 12.15 Biogen Idec
- 12.15.1 Biogen Idec Company Information
- 12.15.2 Biogen Idec Business Overview
- 12.15.3 Biogen Idec Revenue in Anti-tumor Drug Business (2021-2026)
- 12.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
- 12.15.5 Biogen Idec Recent Developments
- 12.16 Eisai
- 12.16.1 Eisai Company Information
- 12.16.2 Eisai Business Overview
- 12.16.3 Eisai Revenue in Anti-tumor Drug Business (2021-2026)
- 12.16.4 Eisai Anti-tumor Drug Product Portfolio
- 12.16.5 Eisai Recent Developments
- 12.17 Teva
- 12.17.1 Teva Company Information
- 12.17.2 Teva Business Overview
- 12.17.3 Teva Revenue in Anti-tumor Drug Business (2021-2026)
- 12.17.4 Teva Anti-tumor Drug Product Portfolio
- 12.17.5 Teva Recent Developments
- 12.18 Otsuka
- 12.18.1 Otsuka Company Information
- 12.18.2 Otsuka Business Overview
- 12.18.3 Otsuka Revenue in Anti-tumor Drug Business (2021-2026)
- 12.18.4 Otsuka Anti-tumor Drug Product Portfolio
- 12.18.5 Otsuka Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst